Lipid Nanoparticles: Nanomedicine’s Triumph

August 6th, 2021|Categories: Perspectives on Current Science|

Oligonucleotide therapeutics have been making headlines this past year, between the groundbreaking new mRNA vaccines and the recent news of phenomenal interim results for Intellia’s investigational genome editing treatment for ATTR amyloidosis. Neither of these would have been possible without a lesser-known component – [...]

A Momentous CRISPR Milestone was Achieved with Remarkable Results

August 1st, 2021|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Intellia Therapeutics and Regeneron Pharmaceuticals’ recent announcement is a major milestone worth celebrating. They shared interim data from the first ever human study using systemically administered CRISPR as a gene editing therapy. Early results that surpassed expectations show that not only is the CRISPR-based therapy [...]

How to test for immune activation by your therapeutic oligonucleotide

June 18th, 2021|Categories: Past Webinars|

Presenter: Arthur M. Krieg, MD, Checkmate Pharmaceuticals Date: 19 April 2018 Description: RNA and DNA oligonucleotides with charged backbones commonly cause immune activation, which can be recognized by appropriate in vitro and/or in vivo testing. Eukaryotic innate immune systems have evolved multiple receptors to [...]

Go to Top